Drug Discovery World

OCTOBER 3, 2022

Join Anne Hammerstein, Ph.D., Product Manager at SPT Labtech, for a fascinating deep dive into the practical considerations of how, when and why you should automate your laboratory’s liquid handling processes. The talk will take place at ELRIG’s Drug Discovery 2022 Tech Theatre, supported by DDW. The event will take place on 4-5 Oct, London Excel, UK and topics will include: The lab of the future is now.

Molecular Biology 244

Molecular Biology Biosimilars Laboratories Doctors 244

Antidote

OCTOBER 7, 2022

Different types of clinical studies are designed to investigate potential therapies, medications, and medical devices — and all of these must go through each phase of a clinical trial before they are approved. This means that volunteers who are willing to participate in research studies are essential to medical breakthroughs and the advancement of knowledge surrounding any given condition.

Research 98

Research Clinical Trials Therapies Trials 98

Drug Channels

OCTOBER 7, 2022

Today’s guest post comes from Jon Lanznar, Chief Strategy Officer at vitaCare Prescription Services from GoodRx. Jon discusses vitaCare , a pharmacy services platform acquired by GoodRx earlier this year. vitaCare helps patients understand coverage, identifies available savings opportunities, and facilitates communications between providers and payers.

Pharmacy 98

Pharmacy Treatment Drugs 98

Drug Patent Watch

OCTOBER 7, 2022

Annual Drug Patent Expirations for TLANDO Tlando is a drug marketed by Antares Pharma Inc and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Antares Pharma drug TLANDO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Discovery World

OCTOBER 7, 2022

The MHRA has approved Colonis’ Melatonin 1mg/ml Oral Solution for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been inadequate. Clinical evidence demonstrates that Melatonin has the potential to decrease sleep latency and increase sleep efficiency in children with ADHD and chronic sleep onset insomnia.

Treatment 130

Treatment Drugs 130

Antidote

OCTOBER 3, 2022

Complement 3 Glomerulopathy, most commonly shortened to C3G or C3G kidney disease, is a rare type of kidney disease that has only been diagnosed since 2013. “C3” refers to a blood protein that has a vital role in the immune system, and “G” is for the damage to glomeruli in the kidneys.

Disease 98

Disease 98

Drug Patent Watch

OCTOBER 7, 2022

Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

OCTOBER 7, 2022

Terebellum and NeurosolvTherapeutics will partner to launch Perineline, a new patented two-part therapy for spinal cord injuries. . The drug has attained EMA Orphan Designation and it is hoped that it will revolutionise the therapeutic treatment and resulting end patient outcomes from spinal cord injuries. . Terebellum will contribute strategic guidance in the pre-commercialisation stage, market access expertise, and supply chain logistics including distribution and fulfilment. .

Treatment 130

Treatment Production Marketing Therapies 130

Advarra

OCTOBER 6, 2022

According to the Food and Drug Administration (FDA), data should meet certain fundamental elements of quality. Whether they’re recorded on paper or electronically, source data should follow ALCOA-C, an acronym used in clinical research for: . Attributable . Legible . Contemporaneous . Original . Accurate . Complete . If these best practices for source documentation aren’t followed, there is no valid evidence the test article is safe and effective. .

Compliance 52

Compliance Clinical Trials Trials Clinical Research 52

Drug Channels

OCTOBER 1, 2022

Today’s guest post comes from Kylie Hall, Director of Product Management at ConnectiveRx. Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Click here to learn about the ConnectiveRx Enterprise Data Platform. Read on for Kylie’s insights.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Production Drugs 98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

OCTOBER 7, 2022

Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

OCTOBER 7, 2022

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery. The research gives insight into the function of immune cells in patients with chemotherapy-resistant breast cancers.

Research 130

Research Immune Response Bioinformatics Treatment 130

Antidote

OCTOBER 5, 2022

Clinical trial patient recruitment is an important aspect of medical research, but unfortunately, it is also one of the challenges. There are many regulations surrounding how information about trials can be shared with patients, and because outreach materials must be approved by the Institutional Review Board (IRB) before a campaign launches, planning a recruitment campaign requires a good deal of forward thinking.

Clinical Trials 52

Clinical Trials Trials Regulations Research 52

Drug Channels

OCTOBER 1, 2022

Today’s guest post comes from Kylie Hall, Director of Product Management at ConnectiveRx. Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Click here to learn about the ConnectiveRx Enterprise Data Platform. Read on for Kylie’s insights.

Pharmaceutical Companies 96

Pharmaceutical Companies Pharmaceuticals Production Drugs 96

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

OCTOBER 7, 2022

Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are twenty-six…. The post New patent for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

OCTOBER 7, 2022

The MHRA has granted marketing authorisation for Eli Lilly’s baricitinib (Olumiant), the first licensed JAK inhibitor for the treatment of severe alopecia areata in adult patients. . The authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both met the primary endpoint of the proportion of patients achieving SALT ?20 (i.e., 80% or more scalp hair coverage) at week 36. .

Therapies 130

Therapies Licensing Licensing Treatment 130

The Open Targets Blog

OCTOBER 3, 2022

The latest release of the Platform — 22.09 — is now available at platform.opentargets.org. Key points New data, in particular: Open Targets Genetics Genomics England PanelApp Gene burden Probes and drugs New data integrity file , in line with FAIR principles Key stats Metric Count Targets 61,888 Diseases 20,931 Drugs 12,854 Evidence 14,229,684 Associations 7,003,171 Additional statistics are available on the Open Targets Community.

Regulations 52

Regulations Disease Drug Development Drugs 52

LifeSciVC

OCTOBER 4, 2022

By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC As one thinks about the iconic break-up lines, it doesn’t take long to come up with: It’s not you; it’s me… I am not ready for a serious relationship right now… I love you but am not “in love” with you… We are at different stages in our lives… If we had only met at another time… Each of them projects a barely veiled attempt to take responsibility for the breakup but not the relationship.

International 40

International 40

Drug Patent Watch

OCTOBER 7, 2022

Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

OCTOBER 6, 2022

Download this 24-page DDW eBook , sponsored by Emulate, to learn about: How microfluidics is fuelling innovation in drug discovery. A detailed look at the organ-on-a-chip sector. How human tissue chips are helping advance our understanding of biology. Download now. The post Using microfluidics in drug discovery appeared first on Drug Discovery World (DDW).

Drugs 130

Drugs Drug Development 130

Advarra

OCTOBER 4, 2022

Clinical trial site selection can make or break a trial’s success before it even begins. The average cost to open an investigator site is estimated at $50,000 1 – a price point compounding quickly when onboarding multiple sites. When you consider around 11% of sites 2 fail to even accrue one participant on a given study, cost savings become a major consideration when evaluating which sites to partner with for a trial.

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

LifeSciVC

OCTOBER 7, 2022

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotechnology, especially of late, requires us to prevail over adversity to deliver for patients. Spero, dedicated to new solutions for patients with infections, has been no exception. In May, we undertook a difficult, but necessary restructuring after a regulatory setback to our lead program tebipenem.

Production 40

Production Marketing 40

Drug Patent Watch

OCTOBER 7, 2022

Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty-three…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

OCTOBER 6, 2022

A new Alzheimer’s disease (AD) treatment has been shown to reduce clinical decline in mild cognitive impairment (MCI) due to AD and mild AD with confirmed presence of amyloid pathology in the brain. . Eisai and Biogen’s anti-amyloid beta (A?) protofibril antibody lecanemab met the primary endpoint and all key secondary endpoints in the global Phase III Clarity AD clinical trial. .

Trials 130

Trials Treatment Clinical Trials Disease 130

The Premier Consulting Blog

OCTOBER 5, 2022

The technology transfer of a manufacturing process to a contract development and manufacturing organization (CDMO) is a key step on the road to developing and commercializing biopharmaceutical products. Successfully executing this step is critical to clearing regulatory expectations, avoiding production delays, and delivering drugs to the market. On the other hand, a failed process technology transfer can lead to problems such as: Delays in starting the first manufacturing batch, due to missing

Small Molecule 52

Small Molecule Production Clinical Trials International 52

Drug & Device Law

OCTOBER 3, 2022

For a decision that affirmed not just a verdict, but an award of punitive damages, against a device manufacturer, Nicholson v. Biomet, Inc. , 46 F.4th 757 (8th Cir. 2022), is not as bad as it could have been. That’s because most of the decision was about evidentiary rulings that the court found to be “harmless” error, and one might even have some benefit for our clients in the long run.

FDA 59

FDA Production Laboratories Trials 59

Drug Patent Watch

OCTOBER 7, 2022

Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

OCTOBER 6, 2022

This 24-page DDW eBook , sponsored by Emulate Bio, contains exclusive insight from industry experts on: How microfluidics is fuelling innovation in drug discovery. A detailed look at the organ-on-a-chip sector. How human tissue chips are helping advance our understanding of biology. This guide is free of charge and you can access here. The post Latest eBook: Using microfluidics in drug discovery appeared first on Drug Discovery World (DDW).

Drugs 130

Drugs 130

Drug Discovery World

OCTOBER 6, 2022

As we start to look beyond the pandemic, which areas of Europe’s drug discovery community should we take note of? Lu Rahman highlights some of the key players. . The European drug discovery sector is buoyant. Valued at $14.8 billion in 2020, the sector is expected to grow by 8.3% until 2030. This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1.

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

Drug Discovery World

OCTOBER 5, 2022

DDW Editor, Reece Armstrong, sits down with Brinter CEO Tomi Kalpio to learn about the company’s approach to bioprinting and how it can be used throughout drug discovery. . Brinter is a provider of 3D bioprinting solutions based in Turku, Finland and the US. The company has developed modular technology that can print multi-material and highly complex tissue structures in 3D, providing all the basic features needed for bioprinting.

Pharmacogenetics 130

Pharmacogenetics Regulations Drugs Therapies 130

Drug Discovery World

OCTOBER 5, 2022

Fragment-based drug discovery (FBDD) is one strategy used to identify novel and potent lead compounds. . Don’t miss out on this free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Fragments are small molecules with a low molecular weight (less than 250 g/mol).

Small Molecule 130

Small Molecule Drugs 130

Drug Discovery World

OCTOBER 5, 2022

Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases. The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness.

Clinical Development 130

Clinical Development Hospitals International Therapies 130

Drug Discovery World

OCTOBER 4, 2022

BioIVT has acquired Fidelis Research, an 85-site clinical biospecimen collection network in Southeastern Europe. . Fidelis Research also possesses cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organisations (CROs). . “This transaction increases BioIVT’s global operations by adding new clinical collection sites, which are predominantly hospital based, focused on oncology, heme-oncology, and autoimmune cases,” said D

Therapies 130

Therapies Pharmaceutical Companies Clinical Research Hospitals 130

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences sector. .

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130